http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Sterile Inflammation after Intravitreal Injection of Aflibercept in a Korean Population
김주영,유용성,권오웅,김순현 대한안과학회 2015 Korean Journal of Ophthalmology Vol.29 No.5
Purpose: To report the frequency and clinical features of sterile inflammation after intravitreal aflibercept injection in a Korean population. Methods: A single-center, retrospective study was performed in patients who received intravitreal aflibercept from July 2013 through January 2015. Results: A total of four cases of post-injection sterile inflammation were identified from 723 aflibercept injections in 233 patients. Patients presented 1 to 13 days after intravitreal aflibercept injection (mean, 5 days). The mean baseline visual acuity was 20 / 60, which decreased to 20 / 112 at diagnosis but ultimately recovered to 20 / 60. Three cases had inflammatory cells in the anterior chamber (mean, 2.25+; range, 0 to 4+), and all cases had vitritis (mean, 3+; range, 2+ to 4+). No patients had pain. Only one patient underwent anterior chamber sampling (culture negative) and injection of antibiotics. Three of four patients were treated with a topical steroid, and all experienced improvement in their symptoms and signs of inflammation. Conclusions: The overall incidence of sterile inflammation after intravitreal aflibercept injection in a Korean population was 4 of 723 injections (0.55%), or 4 of 233 patients (1.79%). Sterile inflammation after intravitreal aflibercept injection typically presents without pain, and the visual outcomes are generally favorable.
이상협,유용성,오현섭 대한안과학회 2020 대한안과학회지 Vol.61 No.7
Purpose: To assess the efficacy and safety of Adalimumab (Humira®, AbbVie, Chicago, IL, USA) for repeated refractory uveitis during systemic steroid or immunosuppressive therapy. Methods: We retrospectively reviewed clinical records on 30 eyes of 18 patients with non-infectious refractory uveitis who underwent Adalimumab injection therapy from December 2017 to July 2019. The therapeutic effect was assessed based on intraocular inflammation grade, central macular thickness, and best corrected visual acuity, and the efficacy was assessed based on control of inflammation and macular edema, as well as corticosteroid sparing effects. The safety was assessed based on adverse events. Results: The mean duration of uveitis at baseline was 55.4 months (13-121 months) and the mean follow-up was 9.2 months (6-18 months). All 30 eyes of 18 patients stopped using systemic steroids and maintained clinical quiescence. Anterior chamber inflammation, vitreous inflammation, and best corrected visual acuity showed significant improvement, and there was no difference in central macular thickness. Uveitis recurred in 5 eyes, but 4 eyes showed controlled inflammation after single posterior sub-tenon steroid injection. One eye was controlled after methotrexate co-administration. Ulticaria (two patients) and injection- site reaction (one patient) were reported as adverse events. Conclusions: Adalimumab is an effective treatment for decreasing inflammatory activity and reducing corticosteroid burden in refractory uveitis. 목적: 전신 스테로이드나 면역억제제 치료 중에도 반복하여 재발하는 난치성 포도막염에서 Adalimumab (Humira®, AbbVie, Chicago, IL, USA)을 사용하여 치료 결과를 평가하고 효용성을 알아보고자 하였다. 대상과 방법: 비감염성 난치성 포도막염으로 Adalimumab 주사치료를 시행한 환자들을 대상으로 후향적으로 임상양상을 비교 분석하였다. 기저질환, 포도막염 양상, 병용치료 약물의 유무, 기존 치료로 발생한 부작용을 조사하였고 치료 전후의 전방과 유리체강 내세포 및 혼탁, 중심황반두께 및 최대교정시력을 비교하였다. 염증과 황반부종의 재발 유무, 병용치료 약물의 조절 여부, 이상반응 발생 사례를 확인하여 Adalimumab 투여의 안전성과 효용성을 평가하였다. 결과: Adalimumab 투여 전 유병기간은 평균 55.4개월(13-121개월)이었으며 주사 후 추적 관찰 기간은 평균 9.2개월(6-18개월)이었다. 18명 30안 모두에서 전신 스테로이드 사용을 중단할 수 있었으며 염증 완화가 확인되었다. 전방과 유리체강내 염증, 최대교정시력은 유의한 호전을 보였으며 중심황반두께는 차이를 보이지 않았다. 5안에서 포도막염의 재발이 발생하였으나 4안은 테논낭하 스테로이드주입술로 염증 조절이 가능하였으며, 1안은 methotrexate 병용 투여 후 조절이 가능했다. Adalimumab 투약 중 발생한 이상 반응은 두드러기(2명)와 주사부위 반응(1명)이 발생하였으며 주사부위 반응 1명은 투약을 중단해야 했다. 결론: Adalimumab은 난치성 포도막염 환자들에서 염증을 완화시키고 전신 스테로이드 투약을 줄일 수 있는 효과적인 치료법이다.
고도근시 환자에서 부분결합간섭계와 초음파를 이용한 생체측정
정진권,최철명,유용성,이성진.JK Chung. M.D.. Chul Myong Choe. M.D.. Yong Sung You. M.D.. Sung Jin Lee. M.D. 대한안과학회 2006 대한안과학회지 Vol.47 No.3
Purpose: To compare the refractive outcome of clear lens extraction employing partial coherence interferometry data with that of applanation ultrasonography. Methods: Thirty eyes of 17 patients with axial length greater than 26 mm who underwent clear lens extraction were enrolled in this study. IOL power was measured using IOLMaster and conventional ultrasonography. Differences between predicted refraction and actual refraction were compared and analyzed according to the biometry method and IOL power calculation formulas. Results: Axial length according to IOLMaster measurement (29.23±1.40 mm) was significantly longer than that measured by ultrasonography (28.68±1.32 mm) (p=0.000). The difference between actual and predicted refraction was 0.75±0.40 diopter by SRK/T with IOLMaster and 0.44±0.52 diopter by SRK/T with A-scan. The standard errors of the two measurement methods were 0.08 and 0.10, respectively. Eighty-five percent and one hundred percent of patients were within 1 diopter, as measured by SRK/T with IOLMaster and with A-scan, respectively. Conclusions: The use of the IOLMaster with the SRK/T formula may be an accurate method of IOL calculation in cases of high myopes, if surgeon factors are corrected for.